Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD-L1 group at the 2018 ASCO.
Microbiome Effects of Antibodies Can Linger for Up to 60 Days Push a start date to allow time between antibiotic use and immunotherapy
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Microbiome Effects of Antibodies Can Linger for Up to 60 Days Push a start date to allow time between antibiotic use and immunotherapy at the 2018 ASCO.
Using Microbiome Transplantation or FMT for RCC They should still benefit from their given immunotherapy with additional supplements
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses tUsing Microbiome Transplantation or FMT for RCC They should still benefit from their given immunotherapy with additional supplements at the 2018 ASCO.
Systemic Therapy in Metastatic Renal Cell Carcinoma Antibiotic use does affect outcomes in patients
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Systemic Therapy in Metastatic Renal Cell Carcinoma Antibiotic use does affect outcomes in patients at the 2018 ASCO.
Dr. Toni Choueiri of the Dana Farber Cancer Institute discusses the subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
Robert Dreicer, MD of the University of Virginia Health System discusses the how soon should we expect approval of immunotherapy in urothelial cancer at ASCO GU 2016.
Future role of immunotherapy and checkpoint inhibitors in urothelial cancer #GU16
Robert Dreicer, MD of the University of Virginia Health System discusses the future role of immunotherapy and checkpoint inhibitors in urothelial cancer at ASCO GU 2016.
Atezolizumab shows very significant activity in advanced urothelial cancer #GU16
Robert Dreicer, MD of the University of Virginia Health System discusses how Atezolizumab shows very significant activity in advanced urothelial cancer at ASCO GU 2016.
Discontinuing VEGF-TT for progression versus toxicity impacts outcomes of second-line therapies in mRCC #GU16
Guillermo De Velasco, MD at Dana Farber discusses discontinuing VEGF-TT for progression versus toxicity impacts outcomes of second-line therapies in mRCC
at ASCO GU 2016
Genomics in urothelial carcinomas may play much bigger role in the future #GU16
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD-L1 group at the 2018 ASCO.